- Home
- UFCS vs JANX Comparison
UFCS vs JANX Comparison
Compare UFCS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | JANX |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 790.3M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UFCS | JANX |
|---|---|---|
| Price | $48.23 | $14.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $40.50 | ★ $47.00 |
| AVG Volume (30 Days) | 85.8K | ★ 879.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | $10,000,000.00 |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | $40.72 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $12.12 |
| 52 Week High | $47.27 | $35.34 |
Technical Indicators
Market Signals| Indicator | UFCS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 78.74 | 43.34 |
| Support Level | $36.27 | $13.88 |
| Resistance Level | N/A | $14.44 |
| Average True Range (ATR) | 1.39 | 0.55 |
| MACD | 0.72 | -0.11 |
| Stochastic Oscillator | 93.05 | 13.63 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.